Bayer has filled a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) requesting marketing approval for its long-acting human Factor VIII therapy, BAY94-9027, to treat hemophilia A. The therapy is designed to allow for dosing at intervals as long as once every seven days. The…
Search results for:
Bayer submitted a Biologics License Application (BLA) to the FDA for BAY94-9027, a long-acting Factor VIII therapy for hemophilia A. The FDA accepted this application for review to treat adolescents and adults with hemophilia A. BAY94-9027 is designed for less frequent dosing, potentially once every seven days, and has shown extended duration in patients' blood.
AI-generated summaries are for informational use only, based on content from multiple pages. They may not reflect full context. For complete details, see the original sources. Consult a qualified healthcare professional for medical advice.
BAY 94‐9027, an investigational factor VIII replacement therapy being developed by Bayer for severe hemophilia A, is able to stay longer in patients’ blood than other standard therapies, according to a study analyzing data from three…
In this series of podcasts from Bloodstream Media and shared by Bloodfeed, host Patrick James Lynch submits questions about hemophilia and other bleeding disorders from listeners to various hemophilia and health care experts. MORE: The Hemophilia CHOICE Project Survey The podcasts feature a pediatric hematologist, Dr. Arash…
In this series of podcasts from Bloodstream Media and shared by Bloodfeed, host Patrick James Lynch submits questions about hemophilia and other bleeding disorders from listeners to various hemophilia and health care experts. MORE: Learn more about the Hemophilia CHOICE Project Survey The podcasts feature a pediatric…
The U.S. Food and Drug Administration (FDA) has accepted Bayer’s Biologics License Application (BLA) filing for BAY94-9027 to treat hemophilia A in adolescents starting at age 12, and in adults. A BLA is a marketing application that covers biological products, as opposed to chemically synthesized ones, and its…
BAY 94-9027, developed by Bayer, is an investigational treatment for severe hemophilia A. It is a PEGylated molecule of recombinant factor VIII in which the B-domain, a region within the factor, is deleted. The therapy is produced using a baby hamster kidney cell line (BHK-21), and has…
In the U.S., hemophilia A is estimated to affect one in every 5,000 male births, hemophilia B one in 25,000 male births, and hemophilia C one in every 100,000 people (males and females). Hemophilia A is thus four times more common than hemophilia B, and about 10 times more common than…
In this series of Bloodstream podcasts from Bloodstream Media and shared by Bloodfeed, host Patrick James Lynch talks to various people in the bleeding disorder community including hematologists, patients, caregivers and advocates about all aspects of living and caring for people with hemophilia and other bleeding disorders.
Hemophilia A is a rare genetic disorder that affects the blood’s ability to clot properly. It is the most common form of hemophilia, responsible for 80% of all cases.